SAN FRANCISCO--(BUSINESS WIRE)--Tempest Therapeutics Inc. presented a poster at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C., describing lead compound TPST-1120’s ...
SAN FRANCISCO--(BUSINESS WIRE)--Tempest Therapeutics Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class immunomodulatory small molecules targeting diverse ...
Tempest Therapeutics presents new data on amezalpat's immune response at the 2025 AACR Annual Meeting, highlighting its cancer treatment potential. Tempest Therapeutics, Inc. announced new data at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback